The company, founded in 2021 and based in Cambridge, Massachusetts, leverages a first-in-class discovery platform called RABID-Seq. This platform uses barcoded viral tracing to gain insights into cell-cell interactions at a single-cell resolution. Violet Therapeutics focuses on developing programs targeting neuroinflammation for various neurodegenerative indications, including Alzheimer's disease. The company operates in stealth mode and aims to identify, map, and mine the cellular connectome at scale.